Epitopea

Executive Summary

Epitopea is a transatlantic cancer immunotherapeutics company pioneering off-the-shelf RNA-based immunotherapies. Its proprietary CryptoMap™ platform identifies a novel class of shared, aberrantly expressed tumor-specific antigens (aeTSAs/Cryptigen™ TSAs) from non-coding 'junk DNA', enabling the development of next-generation cancer vaccines. Founded in 2020 and headquartered in London, the company aims to deliver durable benefits across difficult-to-treat cancers by leveraging these hidden antigens. Epitopea's approach has the potential to overcome key limitations of personalized neoantigen vaccines, offering an accessible, off-the-shelf solution that could be applicable to large patient populations. The company operates in the competitive cancer vaccine space but differentiates via its focus on shared tumor-specific antigens derived from non-coding regions. While still in early stages with no disclosed pipeline details or funding rounds, Epitopea's platform technology has garnered interest. Key risks include preclinical validation, manufacturing scalability, and regulatory pathway clarity. Success hinges on advancing lead candidates toward clinical trials and securing partnerships or financing.

Upcoming Catalysts (preview)

• Q2 2027Lead candidate IND filing40% success
• Q4 2026Series A funding announcement60% success
• Q1 2027Presentation of preclinical data at major conference70% success